1 completed, 1 terminated. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow narlaprevir: new trials by email Literature Review of narlaprevir trials Research Report on narlaprevir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study) Narlaprevir, Ritonavir, Placebo Narlaprevir - Hepatitis C | Phase 3 | Completed | R-Pharm | 420 | 2014-05-07 | 2019-02-07 |
| Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) Boceprevir, Narlaprevir, Peginterferon alfa-2b - Hepatitis C, Chronic, Hepacivirus | Phase 2 / Phase 3 | Terminated | Merck Sharp & Dohme LLC | 1954 | 2007-02-20 | 2018-09-11 |
Hepatitis C (1) · Hepatitis C, Chronic (1)
Merck Sharp & Dohme LLC (1) · R-Pharm (1)
Russia (1)
Mikhail Samsonov (1)